Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perfluorobutane CEUS for HCC Ablation Guidance
NCT05068076Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Open-label, single-arm trial of sonazoid in hepatocellular carcinoma (HCC), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Comparison of treatment response two hours post procedure with Perfluorobutane with routine CECT/CEMRI done at 1 month post procedure. Started Oct 2021; status: completed.
02
Drugs
sonazoid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05068076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05068076.